Nektar Therapeutics (NKTR) Retained Earnings (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Retained Earnings of -$3.8 billion for Q1 2026, down 9756997.44% year-over-year from N/an in Q1 2025, and down 22383570.59% quarter-over-quarter from $17000.0 in Q4 2025.
Powered by 
Analysis
Nektar Therapeutics (NKTR) Retained Earnings (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at -$3.8 billion for Q1 2026.
- In Q1 2026, Retained Earnings fell 9756997.44% year-over-year to -$3.8 billion; the TTM figure through Mar 2026 stood at -$3.8 billion (down 9756997.44% YoY), while the FY2025 annual figure was $17000.0, down 72.13% from the prior year.
- Retained Earnings for Q1 2026 stood at -$3.8 billion, down from $17000.0 in the prior quarter.
- The five-year high for Retained Earnings was $80000.0 in Q4 2023, with the low at -$3.8 billion in Q1 2026.
- The 5-year median for Retained Earnings is -$3.2 billion (2022), against an average of -$1.9 billion.
- The sharpest annual moves came in 2023 and 2026: Retained Earnings jumped 100.0% in 2023, then tumbled 9756997.44% in 2026.
- Nektar Therapeutics' Retained Earnings stood at -$3.2 billion in 2022, then soared by 100.0% to $80000.0 in 2023, then declined by 23.75% to $61000.0 in 2024, then slumped by 72.13% to $17000.0 in 2025, then sank by 22383570.59% to -$3.8 billion in 2026.
- Business Quant data shows NKTR's Retained Earnings at -$3.8 billion in Q1 2026, $17000.0 in Q4 2025, and -$3.7 billion in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Nektar Therapeutics | 2.45 Bn | 1.77 Bn | 3.04 Mn | -3.85 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.85 Bn |
| Mar 31, 2026 | -3.81 Bn |
| Dec 31, 2025 | -3.76 Bn |
| Sep 30, 2025 | -3.72 Bn |
| Jun 30, 2025 | -3.69 Bn |
| Mar 31, 2025 | -3.65 Bn |
| Dec 31, 2024 | -3.60 Bn |
| Sep 30, 2024 | -3.60 Bn |
| Jun 30, 2024 | -3.57 Bn |
| Mar 31, 2024 | -3.51 Bn |
| Dec 31, 2023 | -3.48 Bn |
| Sep 30, 2023 | -3.44 Bn |
| Jun 30, 2023 | -3.39 Bn |
| Mar 31, 2023 | -3.34 Bn |
| Dec 31, 2022 | -3.20 Bn |
| Sep 30, 2022 | -3.14 Bn |
| Jun 30, 2022 | -3.08 Bn |
| Mar 31, 2022 | -2.92 Bn |
| Dec 31, 2021 | -2.83 Bn |
| Sep 30, 2021 | -2.69 Bn |